Quetiapine in bipolar disorder: Increasing evidence of efficacy and tolerability

Drugs of Today

Volumn 40, Issue 10, 2004, Pages 837-852

  Cole, Patrick ^a   Rabasseda, Xavier ^a  

^a Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; EMONAPRIDE; FLUPERLAPINE; HALOPERIDOL; LITHIUM; MESSENGER RNA; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NEUROTENSIN; OLANZAPINE; PERLAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; THIORIDAZINE; TRANQUILIZER; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; ASTHENIA; BIPOLAR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSOMNIA; MANIA; META ANALYSIS; MONOTHERAPY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; PHARMACOKINETICS; QT PROLONGATION; QUALITY OF LIFE; RECEPTOR OCCUPANCY; REVIEW; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; MULTICENTER STUDIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8744226996     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.10.863744     Document Type: Review

References (59)

1. Sachs, G.S., Printz, D.J., Kahn, D.A., Carpenter, D., Docherty, J.P. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med Special Report 2000 (April): 1-104.
2. Vestergaard, P., Aagaard, J. Five year mortality in lithium-treated manic-depressive patients. J Affect Discord 1991, 21: 33-8.
3. Kasper, S., Stamenkovic, M., Letmaier, M. et al. Atypical antipsychotics in mood disorders. Int Clin Psychopharmacol 2002, 17: S1-S10.
4. Casey, P., Robinson, K.A., Castañer, J. Quetiapine fumarate. Drugs Fut 1996, 21: 483.
5. Lisd, J.D., Dime-Meenan, S., Whybrow, P.C. et al. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994, 31: 281-94.
6. Bowden, C.L. Update on bipolar disorder: Epidemiology, etiology, diagnosis, and prognosis. Medscape Mental Health 1997, 2.
7. Raggi, M.A. Therapeutic drug monitoring: Chemical-clinical correlations of atypical antipsychotic drugs. Curr Medicinal Chem 2002, 9: 1397-14O9.
8. Yatham, L.N. Mood stabilization and the role of antipsychotics. Int Clin Psychopharmacol 2002, 17: S21-S27.
9. Mir, S., Taylor, D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001, 16: 63-73.
10. Nasrallah, H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003, 28 (Suppl. 1): 83-96.
11. Cutler, A.J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003, 28 (Suppl. 1): 69-82.
12. Suppes, P. Treatment of bipolar disorder with atypical antipsychotics. Mood Disorder Symposium, 7th World Congress of Biological Psychiatry (July 6-11, Berlin) 2001.
13. Sussman, N. et al. Choosing an atypical antipsychotic. Int Clin Psychopharmacol 2002, 17: S29-S33.
14. Zarate Jr., C., Rothschild, A., Fletcher, K.E. et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000, 61: 185-9.
15. Nemeroff, C.B., Kinkead, B., Goldstein, J. Quetiapine: Preclinical studies, pharmacokinetics, drug interactions and dosing. J Clin Psychiatry 2002, 63 (Suppl. 13): 5-11.
16. Adityanjee, M.D., Schulz, S.C. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002, 63 (Suppl. 13): 32-8.
17. Gefvert, O., Lundberg, T., Wieselgren, I.M. et al. D-2 and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001, 11: 105-10.
18. Meats, P. An effective and well-tolerated atypical antipsychotic. Int J Psych Clin Pract 1997, 1: 231-9.
19. Goldstein, J.M. Atypical antipsychotic drugs: Beyond acute psychosis, new directions. Expert Opin Emerg Drugs 1999, 4: 127-51.
20. Jones, H.M., Travis, M.J., Mulligan, R. et al. In vivo 5-HT2A receptor blockade by quetiapine-An R91150 single photon emission tomography study. Psychopharmacol 2001, 157: 60-6.
21. Tarazi, F.I., Zhang, K., Baldessarini, R.J. et al. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001, 297: 711-7.
22. Goldstein, J.M., Litwin, L.C., Sutton, E.B., Malick, J.B. Seroquel: Electrophysical profile of a potential atypical antipsychotic. Psychopharmacology 1993, 112: 293-8.
23. Migler, B.M., Warawa, E.J., Malick, J.B. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 1003, 112: 299-307.
24. Deveney, A.M., Waddington, J.L. Effects of olanzapine and ICI 204,636 on behavioral responses to the "D2-like" dopamine receptor agonist RU 24213: Comparison with clozapine. Brit J Pharmacol 1994, 113 (Suppl.): Abstr. 14P.
25. Deveney, A.M., Waddington, J.L. Effects of olanzapine and ICI 204,636 on behavioral responses to the "D1-like" dopamine receptor agonist A-68930: Comparison with clozapine. Brit J Pharmacol 1995, 114 (Suppl.): Abstr. 120P.
26. Devane, C.L., Nemeroff, C.B. Clinical pharmacokinetics of quetiapine - An atypical antipsychotic. Clin Pharmacokinet 2001, 40: 509-22.
27. Potkin, S.G., Thyrum, P.T., Bera, R. et al. Openlabel study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther 2002, 24: 1809-23.
28. Potkin, S.G., Thyrum, P.T., Alva, G. et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002, 22: 121-30.
29. Potkin, S.G., Thyrum, P.T., Alva, G. et al. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol 2002, 22: 174-82.
30. Strakowski, S.M., Keck, P.E., Wong, Y.W.J. et al. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol 2002, 22: 201-5.
31. Wong, Y.W.J., Yeh, C., Thyrum, P.T. et al. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001, 21: 89-93.
32. DeVane, C.L., Winter, H., Smith, M.A. Open-label pharmacokinetic study of quetiapine plus divalproex in patients with schizophrenic/schizoaffective disorders or bipolar disorder. Int J Psychiatry Clin Pract 2003, 7: 290-321, Abstr. P08.
33. Sajatovic, M., Brescan, D.W., Perez, D.E. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry 2001, 62: 728-32.
34. Mullen, J., Jibson, M.D., Sweitzer, D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001, 23: 1839-54.
35. Sajatovic, M., Mullen, J.A., Sweitzer, D.E. et al. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 2002, 63: 1156-63.
36. Fleming, K., Kahali, A., Yeh, C., Vargo, D.L., Thyrum, P.T., Potkin, S. Neurocognitive effects of "Seroquel" (ICI 204,636). 10th World Congr Psychiatry (Aug 23-28, Madrid) 1996, Abstr. 305.
37. Lee, M.A., Meltzer, H.Y. Quetiapine improves cognitive function in schizophrenia. 7th World Cong Biol Psychiatry (Jul 1-6, Berlin) 2001, Abstr. P021-11.
38. McConville, B., Carrero, L., Sweitzer, D. et al. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial. J Child Adolesc Psychopharmacol 2003, 13: 75-82.
39. Alston, J.F. Remission of treatment-resistant bipolar disorder I with quetiapine in an adolescent. Poster presented at 7th World Congress of Biological Psychiatry (WCBP) annual meeting (July 1-6, Berlin) 2001, Abstr. 28.
40. Altamura, C., Madaro, D., Salvadori, D. et al. Quetiapine in acute mania: A case report (With a six-month follow-up). Int J Psychiatr Clin Pract 2001, 5: 283-85.
41. Ghaemi, S.N., Katzow, J.J. The use of quetiapine for treatment-resistant bipolar disorder:. A case series. Ann Clin Psychiatry 1999, 11: 137-40.
42. Chisholm, K., Dennehy, E., Suppes, T. Clinical response to quetiapine add-on for treatment refractory bipolar disorder. Poster presented at the 4th International Conference on Bipolar Disorder (June 14-16, Pittsburgh) 2001, Abstr. 28.
43. Dunayevich, E. Quetiapine in the treatment of mania. Poster presented at 7th World Congress of Biological Psychiatry (WCBP) annual meeting (July 1-6, Berlin) 2001.
44. Vieta, E., Parramon, G., Padrell, E. et al. Quetiapine in the treatment of rapid cycling bipolar disorder. Bipolar Disord 2002, 4: 335-40.
45. Ghaemi, S.N., Goldberg, J.F., Henry, C.A. et al. Quetiapine for rapid-cycling bipolar disorder: A long-term follow-up study. Bipolar Disord 2003, 5 (Suppl. 1): 50.
46. Suppes, T., McElroy, S.L., Keck, P.E. et al. Use of quetiapine in bipolar disorder: A case series with prospective evaluation. Int Clin Psychopharmacol 2004, 19: 173-4.
47. Keck, P.E., Jr. New antiepileptics in the treatment of bipolar disorder. Am Psychiatric Assoc Meeting (May 5-10, New Orleans) 2001, Abstr. 34E.
48. Post, R.M., Leverich, G.S., Altshuler, L.L. et al. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003, 5: 310-19.
49. Sokolski, K.N., Denson, T.F. Adjunctive quetiapine in bipolar patients partially responsive to lithium or valproate. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27: 863-6.
50. Delbello M.P., Schwiers, M.L., Rosenberg, H.L., Strakowski, S.M. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002, 41: 1216-23.
51. Reimherr, F.W. Quetiapine effectively treats bipolar disorder and attention-deficit/hyperactivity disorder in adolescent patients. Presented at the American Psychiatric Association-53rd Institute on Psychiatric Services, Orlando, October 2001.
52. Brown, E.S., Nejtek, V.A., Perantie, D.C. et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002, 4: 406-11.
53. Sachs, G., Chengappa, K., Suppes, T. et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: A randomized, double-blind, placebo-controlled study. Bipolar Disord 2004, 6: 213-23.
54. Yatham, L.N., Paulsson, B., Mullen, J., Vågerö, M. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacology 2004, 24: in press.
55. Jones, M., Huizar, K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2). Bipolar Disord 2003, 5: 57, Abstr. P95.
56. McFadden, W., Calabrese, J.R., McCoy, R., Minkwitz, M., Wilson, E., Mullen, J. Anti-anxiety effects analysis of quetiapine in bipolar depression. Ann Meet American Psychiatric Association (May 1-6, New York) 2004.
57. Calabrese, J.R. Efficacy and tolerability of quetiapine monotherapy for major depressive episodes in patients with bipolar disorder. Ann Meet American Psychiatric Association (May 1-6, New York) 2004.
58. Shimade, E., Murasaki, M., Miora, S., Sadakuni, F., Yoshimoto, W. A phase I study in healthy volunteers of ICI 204,636, a novel neuroleptic agent. Can J Physiol Pharmacol 1994, 72 (Suppl. 1): Abstr. P13.22.11.
59. Atmaca, M., Kuloglu, M., Tezcan, E. et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res 2002, 33: 562-65.